What question did this study set out to answer?

To evaluate the safety of GLP-1 and dual GLP-1/GIP receptor agonists during preconception, pregnancy, and lactation.

March 28, 2026

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes

Key Points

To evaluate the safety of GLP-1 and dual GLP-1/GIP receptor agonists during preconception, pregnancy, and lactation.
Conducted a systematic review of existing literature
Assessed maternal, fetal, and neonatal outcomes
Focused on GLP-1-based therapies in early pregnancy
No consistent evidence of increased maternal risk was found
Fetal and neonatal risks appear minimal with early exposure
Limited data exists on the safety of continued use throughout pregnancy

Abstract

Current evidence suggests that preconceptional or early-pregnancy exposure to GLP-1-based therapies is not consistently associated with increased maternal, fetal, or neonatal risk, although data on continued use throughout gestation remain limited.

Mark Helpful

Bookmark

Relay